J. Charrier

发表

Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970

P. Reaper, P. Charlton, J. Pollard, 2014, Oncotarget.

Advances in the design of ITK inhibitors

J. Charrier, Ronald Knegtel, Ronald M. A. Knegtel, 2013, Expert opinion on drug discovery.

Synthesis and evaluation of novel prodrugs of caspase inhibitors.

P. Weber, J. Charrier, J. Studley, 2012, Bioorganic & medicinal chemistry letters.

A complementary route to diaminopyrimidines through regioselective SNAr amination reactions

J. Charrier, Michael O'donnell, 2015 .

The discovery of the potent aurora inhibitor MK-0457 (VX-680).

David Bebbington, Michael O'Donnell, Damien Fraysse, 2009, Bioorganic & medicinal chemistry letters.

1,2-Bis[(2-dimethylamino-2-thioxo-1-phenylethylidene)hydrazino]ethane: a new tetradentate ligand for Ni2+

J. Meslin, D. Deniaud, J. Charrier, 2001 .

SYNTHESIS OF A NEW TYPE OF N2S2 TETRADENTATE LIGAND

J. Meslin, J. Charrier, A. Reliquet, 1998 .

Reinvestigation of the alkylation of pyroglutamate ester urethanes

P. Hitchcock, D. W. Young, J. Charrier, 1998 .

Diastereoselective synthesis of 3,6-dihydro-2H-1,3,4-thiadiazines

J. Meslin, J. Charrier, A. Reliquet, 1998 .

STABLE α-HYDRAZONOTHIOACETOPHENONES USED AS HETERODIENES

J. Meslin, J. Charrier, A. Reliquet, 1995 .

From benzil arylimines to 2H-benzo-1,4-thiazines, benzothiazoles or indoles

J. Meslin, D. Deniaud, J. Charrier, 2001 .

Synthesis, Structural and Biological Studies of Ubiquitin Mutants Containing (2S, 4S)‐5‐Fluoroleucine Residues Strategically Placed in the Hydrophobic Core

N. C. Price, D. Uhrín, H. McSparron, 2003, Chembiochem : a European journal of chemical biology.

Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.

P. Reaper, J. Pollard, M. Mortimore, 2011, Journal of medicinal chemistry.

Synthesis of (2S,4S)- and (2S,4R)-5-fluoroleucine and (2S,4S)-[5,5-2H2]-5-fluoroleucine.

P. Hitchcock, D. W. Young, J. Charrier, 2004, Organic & biomolecular chemistry.

Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor.

P. Reaper, J. Golec, M. Griffiths, 2019, Journal of medicinal chemistry.

Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR.

P. Reaper, P. Charlton, J. Pollard, 2011, Nature chemical biology.

Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors.

A. Tanner, H. Twin, J. Jiménez, 2011, Journal of medicinal chemistry.

Synthesis of (2S,3S)-3'-fluoroisoleucine.

P. Hitchcock, D. W. Young, J. Charrier, 2004, Organic and biomolecular chemistry.

2-Chloro-4-tetrafluorophenoxypyrimidine: a versatile reagent for C-2 prior to C-4 functionalizations

J. Charrier, Michael O'donnell, 2016 .

2-Chloro-4-tetrafluorophenoxypyrimidine: A Versatile Reagent for C-2 Prior to C-4 Functionalizations.

J. Charrier, Michael O'donnell, 2016 .

Synthesis of (2S,3R)-[3',3',3'-2H3]-valine and (2S,3S)-4-fluorovaline.

P. Hitchcock, D. W. Young, J. Charrier, 2004, Organic & biomolecular chemistry.

Unusual stereoselectivity in the alkylation of pyroglutamate ester urethanes

P. Hitchcock, D. W. Young, J. Charrier, 2001 .

Unusual Stereoselectivity in the Alkylation of Pyroglutamate Ester Urethanes.

P. Hitchcock, D. W. Young, J. Charrier, 2002 .

Advances in the design of ITK inhibitors

J. Charrier, Ronald M. A. Knegtel, 2013, Expert opinion on drug discovery.

Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970

P. Reaper, P. Charlton, D. Newsome, 2014, Oncotarget.

The discovery of the potent aurora inhibitor MK-0457 (VX-680).

M. Mortimore, D. Kay, D. Bebbington, 2009, Bioorganic & medicinal chemistry letters.

Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.

P. Reaper, M. Mortimore, D. Kay, 2011, Journal of medicinal chemistry.